Gender differences in pharmacokinetics of oral warfarin in rats

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 4, 2005, Pages 147-150

  Zhu, Xuan ^a   Shin, Wan G ^a  

^a Seoul National University   (South Korea)

Author keywords

CYP isozymes; Gender difference; Pharmacokinetics; Rats; Warfarin

Indexed keywords

WARFARIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; WARFARIN;

EID: 19144367186     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.442     Document Type: Article

References (15)

1. Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984; 9: 189-202.
2. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-239.
3. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16: 348-354.
4. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Rowland M. Warfarin: Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-1617.
5. Park BK. Warfarin metabolism and mode of action. Biochem Pharmacol 1988; 37: 67-74.
6. Rettie AR, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-59.
7. Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993; 43: 234-239.
8. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: Stereochemical considerations. Clin Pharmacol Ther 1986; 39: 15-24.
9. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes: A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996; 24: 610-614.
10. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 1989; 17: 265-270.
11. Kaminsky LS, Guengerich FP, Dannan GA, Aust SD. Comparisons of warfarin metabolism by liver microsomes of rats treated with a series of polybrominated biphenyl congeners and by the component-purified cytochrome P-450 isozymes. Arch Biochem Biophys 1983; 225: 398-404.
12. Lewis DFV. P450. Substrate specificity and metabolism. In Cytochrome P450. Structure, Function and Mechanism, Lewis DFV (ed.). Taylor & Francis: Bristol, 1996; 123.
13. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
14. Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999; 51: 175-180.
15. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.